X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
P&G: Two product wonder - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Nov 20, 2000

    P&G: Two product wonder

    Procter and Gamble Hygiene and Healthcare (PGHH) is the 65% subsidiary of Procter & Gamble, USA, a US$ 38 bn consumer products major. The Indian subsidiary is the market leader in the anti-cold healthcare (Vicks) segment and feminine care (Whisper sanitary napkins). The company being the least cost producer of Vicks Vaporub among P&G facilities worldwide is the sourcing base for all P&G subsidiaries in Asia.

    To lend focus to its business, PGHH consciously decided to be present only in two products viz. Vicks and Whisper. Thus it exited from the shampoo segment by selling Mediker (anti-lice shampoo) to Marico Industries for Rs 100 m. Realising that it cannot match the distribution strengths which compatriot Hindustan Lever (HLL) possessed, it truncated its distribution network and signed a distribution agreement with Marico for Clearasil, Old Spice, Camay range of soaps and Ariel detergent bar. PGHH also terminated its manufacturing agreement for shampoos with P&G Home Products, its parents' 100% subsidiary.

    P&G's strategy has revolved around premium positioning of both its product categories. In a sense, the company has been focussing on margins (value) rather than volumes. But competition from products such as Dcold and Smyle has impacted the sales of Vicks cough drops and forced the company to increase ad spends. The company’s ad spend has consistently been on the rise. In FY99, PGHH advertisement expenditure as a percentage of turnover was 6.7%. In FY00, it increased to 9%. This has put pressure on the company’s margins.

    The anti-cold healthcare segment registered a marginal 1.5% sales growth overall in FY00, with Vicks maintaining a 40% hold on this segment. But in sanitary napkins segment, Whisper continues to be the market leader with a 50% share despite the onslaught of cheaper products from competitors like Johnson and Johnson and HLL. Sales in this segment registered a 2% growth during FY00.

    Given the company's clear strategy on focusing on two products, as also its premium positioning, the company is better placed than most FMCG companies to clock double-digit growth figures both in its topline and bottomline in the medium term. In the long term however, P&G's two-product focus might become a bane as competition picks up. To keep competition at bay, the company will have to keep increasing its ad spends, which in the long term is negative. There are also concerns regarding its parent's two 100% subsidiaries in India.

    The stock trades at a P/e multiple of 18 times its FY00 earnings, which look reasonable given the company’s dominance in its current businesses and the margins it earns.

     

     

    Equitymaster requests your view! Post a comment on "P&G: Two product wonder ". Click here!

      
     

    More Views on News

    P&G: Strong Core Growth (Quarterly Results Update - Detailed)

    Dec 9, 2016

    Procter & Gamble Hygiene and Health Care has announced the first quarter results of the financial year ended June 2017 (1QFY17). The company's sales rose by 12.5%YoY while net profit rose by 50.1% YoY during the quarter.

    P&G: Strong Core Performance (Quarterly Results Update - Detailed)

    Oct 5, 2016

    Procter & Gamble Hygiene and Health Care reported a 0.1% YoY growth in sales and a 2.2% YoY increase in net profits during the quarter ended June 2016.

    Marico: Earnings Hit by Lower Volumes and Firming Input Prices (Quarterly Results Update - Detailed)

    Aug 9, 2017

    While GST implementation brought down volumes and profitability in the short run, Marico remains optimistic in the long run.

    P&G: A Stable Quarter (Quarterly Results Update - Detailed)

    May 6, 2016

    Procter & Gamble Hygiene and Health Care reported an 11% YoY increase in revenues, while profits rose by 12% YoY during the quarter.

    P&G: Margins Go Through the Roof (Quarterly Results Update - Detailed)

    Feb 9, 2016

    Procter & Gamble Hygiene and Health Care reported an 11% YoY increase in revenues, while profits rose by 62% YoY during the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    P&G HYGIENE SHARE PRICE


    Aug 18, 2017 10:45 AM

    TRACK P&G HYGIENE

    • Track your investment in P&G HYGIENE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    P&G HYGIENE 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE P&G HYGIENE WITH

    MARKET STATS